View Older Stories View More Recent Stories

Apr 3, 2017 10:00AM Sigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors
Mar 31, 2017 04:06PM Pfenex (PFNX) Announces Retirement of Chairman And Board Member William Rohn
Mar 31, 2017 04:05PM William R. Rohn Announces Plans To Retire As Chairman And Board Member
Mar 15, 2017 04:05PM Pfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update
Mar 1, 2017 08:00AM Pfenex To Report Fourth Quarter and Full Year 2016 Results and Provide Business Update on Wednesday, March 15, 2017
Feb 10, 2017 06:00AM Pfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference
Jan 24, 2017 08:00AM Pfenex Announces Leadership Transition
Dec 1, 2016 05:00PM Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules
Nov 9, 2016 04:05PM Pfenex Reports Third Quarter 2016 Results and Provides Business Update
Oct 26, 2016 06:30PM Pfenex To Report Third Quarter 2016 Results and Provide Business Update on Wednesday, November 9, 2016
Oct 3, 2016 06:00PM Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules
Aug 8, 2016 07:32AM Pfenex (PFNX) Announces Positive Results for Px563L Anthrax Vaccine Study
Aug 8, 2016 07:31AM Pfenex (PFNX) Will Regain Full Rights to Lucentis Biosimilar PF582
Aug 8, 2016 07:30AM Pfenex Reports Second Quarter 2016 Results and Provides Business Update
Aug 8, 2016 07:30AM Pfenex Announces Positive Anthrax Vaccine Study Results
Aug 8, 2016 07:30AM Pfenex to Regain Full Rights to PF582 and Announces Phase 1/2 Results
Jul 28, 2016 04:08PM Jazz Pharma (JAZZ), Pfenex (PFNX) Enter Hematological Malignancies-Related Licensing Agreement
Jul 28, 2016 04:05PM Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
Jul 28, 2016 04:05PM Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
Jul 27, 2016 08:30AM Pfenex To Report Second Quarter 2016 Results and Provide Business Update on Monday, August 8, 2016
May 9, 2016 05:42PM Pfenex (PFNX) Announces Positive Top-Line Bioequivalence Data for PF708
May 9, 2016 04:05PM Pfenex Reports Positive Top-Line Bioequivalence Data for PF708
May 9, 2016 04:05PM Pfenex Reports First Quarter 2016 Results and Provides Business Update
Apr 25, 2016 08:00AM Pfenex to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference
Apr 21, 2016 08:00AM Pfenex To Report First Quarter 2016 Results and Provide Business Update on Monday, May 9, 2016
Mar 10, 2016 04:05PM Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update
Mar 7, 2016 08:30AM Pfenex to Present at the 2016 Barclays Global Healthcare Conference
Feb 25, 2016 08:00AM Pfenex To Report Fourth Quarter and Full Year 2015 Results and Provide Business Update on Thursday, March 10, 2016
Feb 23, 2016 11:27AM Pfenex CEO and Biosimilars Council Chair Dr. Bert Liang to Host Panel Discussion on Key Biosimilar Issues at GPhA Annual Meeting
Nov 13, 2015 08:00AM Pfenex Reports Third Quarter 2015 Results and Provides Business Update
Oct 27, 2015 08:30AM Pfenex To Report Third Quarter 2015 Results and Provide Business Update on Friday, November 13, 2015
View More Recent Stories View Older Stories